Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials

Authors

Bengt Hoepken (ORCID: https://orcid.org/0000-0002-7487-8559)
Sarah Kavanagh (ORCID: https://orcid.org/0000-0003-0341-8261)
Nina Magnolo (ORCID: https://orcid.org/0000-0001-6802-0153)
José Manuel López Pinto
Wolf‐Henning Boehncke (ORCID: https://orcid.org/0000-0002-1225-7124)
James G. Krueger (ORCID: https://orcid.org/0000-0002-3775-1778)
Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
Paolo Gisondi (ORCID: https://orcid.org/0000-0002-1777-9001)
Bruce E Strober (ORCID: https://orcid.org/0000-0002-8394-2057)
Ronald Vender

Institutions

University of Geneva (CH)
University of Verona (IT)
Manchester Academic Health Science Centre (GB)
Yale University (US)
University Hospital Münster (DE)
Central Dermatology (US)
Dermatrials Research (CA)
Bupa Cromwell Hospital (GB)
NIHR Manchester Biomedical Research Centre (GB)
UCB Pharma (Germany) (DE)
Rockefeller University (US)

Publication Details

Journal: Dermatology and Therapy
Published: 2025-10-08
DOI: https://doi.org/10.1007/s13555-025-01557-1
Primary Topic: Psoriasis: Treatment and Pathogenesis
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
Sanofi
Biogen
Celgene
Regeneron Pharmaceuticals
Valeant Pharmaceuticals International
Incyte
National Institute for Health and Care Research
Meiji Seika Pharma
Sun Pharma
LEO Pharma
Allergan
Manchester Biomedical Research Centre

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials

Bengt Hoepken, Sarah Kavanagh, Nina Magnolo, José Manuel López Pinto et al.

Oct 8, 2025

Dermatology and Therapy

Psoriasis: Treatment and Pathogenesis

article

Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials

Bengt Hoepken, Sarah Kavanagh, Nina Magnolo, José Manuel López Pinto, Wolf‐Henning Boehncke, James G. Krueger, Richard Bruce Warren, Paolo Gisondi, Bruce E Strober, Ronald Vender

October 8, 2025article en

Abstract

No abstract available for this paper.

Dermatology and TherapyVol. 15(12)

University of Geneva (CH), University of Verona (IT), Manchester Academic Health Science Centre (GB), Yale University (US), University Hospital Münster (DE), Central Dermatology (US), Dermatrials Research (CA), Bupa Cromwell Hospital (GB), NIHR Manchester Biomedical Research Centre (GB), UCB Pharma (Germany) (DE), Rockefeller University (US)

Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Biogen, Celgene, Regeneron Pharmaceuticals, Valeant Pharmaceuticals International, Incyte, National Institute for Health and Care Research, Meiji Seika Pharma, Sun Pharma, LEO Pharma, Allergan, Manchester Biomedical Research Centre

Openalex Percentile: Top 71%

Psoriasis: Treatment and Pathogenesis

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials — Bengt Hoepken, Sarah Kavanagh, et al. · Dermatology and Therapy (2025) | TGRS Research Map | TGRS